The trajectory of companies tied to iconic drugs like Viagra presents a nuanced investment landscape . While the initial boom of copyright, fueled by Viagra's remarkable popularity, generated substantial profits , the expiry in key regions has introduced considerable volatility. Investors are now grappling with the consequences of rival medications